ERBB2 and breast carcinoma: The efficacy and safety of adding a third agent (cytotoxic or biologic) to BM/taxane regimen was evaluated in a recent meta‐analysis including seven randomized trials and 1,124 HER2‐negative advanced breast cancer patients treated in first‐line setting (Liu et al., 2016).